Austin-based neurotechnology startup Paradromics Inc. has successfully completed its first human implantation of the Connexus Brain-Computer Interface (BCI), marking a significant advancement in the field of neurotechnology. The procedure was performed on a patient undergoing epilepsy surgery, with the implant aiming to assist individuals with communication impairments resulting from conditions such as ALS, spinal cord injuries, or strokes.
The Connexus BCI, smaller than a dime, is designed to translate neural signals into digital commands, potentially enabling users to communicate through thought alone. Paradromics’ approach involves direct implantation into brain tissue, distinguishing it from other neurotech companies that utilize less invasive methods.
This milestone positions Paradromics as a notable competitor to Elon Musk’s Neuralink, which has also been developing implantable BCIs. The successful implantation signifies Paradromics’ transition into a clinical-stage company, with plans to initiate broader clinical trials pending regulatory approval.
Founded in 2015, Paradromics has secured over $105 million in venture funding, along with $18 million in grants from the National Institutes of Health and the Defense Advanced Research Projects Agency. The company’s 60-person team in Austin is focused on advancing the development and application of the Connexus BCI.
The potential applications of BCIs extend beyond communication assistance, with implications for treating various neurological conditions and enhancing human-computer interaction. As Paradromics progresses with its clinical trials, the outcomes could have significant impacts on the future of neurotechnology and patient care.
Source: MySanAntonio
Image source: Paradromics
